ABSTRACT
The Koo–Menter Psoriasis Instrument (KMPI) has been designed to be a practical assessment tool, which dermatologists can quickly and easily use in their daily practice to help guide them in identifying patients with psoriasis who may be candidates for systemic therapy. The physician uses the psoriasis-specific quality-of-life score, the total percentage of body surface area involvement, and the overall clinical assessment of the patient’s psoriasis to determine the need for systemic therapy. The KMPI provides a quick and easy way to identify and document patients with psoriasis who require systemic therapy. The physician’s global assessment, sometimes called investigator’s global assessment or psoriasis global assessment is a nonstandard approach to assessing psoriasis using various terminologies. The KMPI has the potential to improve physician–patient communication by involving the patient in characterizing their disease and its impact on their lives.
